지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2023.2
- 수록면
- 61 - 73 (13page)
이용수
초록· 키워드
오류제보하기
Objectives: Prophylactic vaccines against high-risk human papillomaviruses (HR-HPVs) hold promise to prevent the development of higher grade cervical intraepithelial neoplasia (CIN 2+) and cervical cancer (CC) that develop due to HR-HPV genotypes that are included in HPV vaccines, but women will continue to develop CIN 2+ and CC due to HR-HPV genotypes that are not included in the quadrivalent HPV vaccine (qHPV) and 9-valent HPV vaccine (9VHPV). Thus, the current vaccines are likely to decrease but not entirely prevent the development of CIN 2+ or CC. The purpose of the study was to determine the prevalence and determinants of CIN 2+ that develop due to HR-HPVs not included in vaccines.
Methods: Study population consisted of 1476 women tested for 37 HPVs and known to be negative for qHPVs (6/11/16/18, group A, n = 811) or 9VHPVs (6/11/16/18/31/33/45/52/58, group B, n = 331), but positive for other HR-HPVs. Regression models were used to determine the association between plasma concentrations of micronutrients, socio-demographic, lifestyle factors and risk of CIN 2+ due to HR-HPVs that are not included in vaccines.
Results: The prevalence of infections with HPV 31, 33, 35 and 58 that contributed to CIN 2+ differed by race. In group A, African American (AA) women and current smokers were more likely to have CIN 2 (OR = 1.76, P = 0.032 and 1.79, P = 0.016, respectively) while in both groups of A and B, those with higher vitamin B12 were less likely to have similar lesions (OR = 0.62, P = 0.036 and 0.45, P = 0.035, respectively).
Conclusions: We identified vitamin B12 status and smoking as independent modifiable factors and ethnicity as a factor that needs attention to reduce the risk of developing CIN 2+ in the post vaccination era. Continuation of tailored screening programs combined with non-vaccine-based approaches are needed to manage the residual risk of developing HPVrelated CIN 2+ and CC in vaccinated women.
Methods: Study population consisted of 1476 women tested for 37 HPVs and known to be negative for qHPVs (6/11/16/18, group A, n = 811) or 9VHPVs (6/11/16/18/31/33/45/52/58, group B, n = 331), but positive for other HR-HPVs. Regression models were used to determine the association between plasma concentrations of micronutrients, socio-demographic, lifestyle factors and risk of CIN 2+ due to HR-HPVs that are not included in vaccines.
Results: The prevalence of infections with HPV 31, 33, 35 and 58 that contributed to CIN 2+ differed by race. In group A, African American (AA) women and current smokers were more likely to have CIN 2 (OR = 1.76, P = 0.032 and 1.79, P = 0.016, respectively) while in both groups of A and B, those with higher vitamin B12 were less likely to have similar lesions (OR = 0.62, P = 0.036 and 0.45, P = 0.035, respectively).
Conclusions: We identified vitamin B12 status and smoking as independent modifiable factors and ethnicity as a factor that needs attention to reduce the risk of developing CIN 2+ in the post vaccination era. Continuation of tailored screening programs combined with non-vaccine-based approaches are needed to manage the residual risk of developing HPVrelated CIN 2+ and CC in vaccinated women.
목차
ABSTRACT
Introduction
Methods
Results
Discussion
Conclusions
References
참고문헌 (0)
참고문헌 신청함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Overview of the Efficacy of Human Papillomavirus Virus Vaccines
JOURNAL OF BACTERIOLOGY AND VIROLOGY
2020 .09
-
Current and Next-generation Vaccines against Human Papillomaviruses
JOURNAL OF BACTERIOLOGY AND VIROLOGY
2015 .09
-
부산지역 여성의 자궁경부질환과 HPV의 상관관계
대한임상검사과학회지
2019 .01
-
A Review of HPV Prevalence Research
JOURNAL OF BACTERIOLOGY AND VIROLOGY
2020 .09
-
Analytical Performance of Sensitivity and Specificity for Rapid Multiplex High Risk Human Papillomavirus Detection Kit: HPV ViroCheck
대한임상검사과학회지
2017 .01
-
Evaluation of human papillomavirus (HPV) genotyping assays using type-specific HPV L1 reference DNA
Genes & Genomics
2021 .01
-
Influence of the Host Factors on Human Papillomavirus Infection and Vaccine Efficacy
JOURNAL OF BACTERIOLOGY AND VIROLOGY
2015 .09
-
Human Papillomavirus Prevalence and Distribution according to Age among Korean and Chinese Women
대한임상검사과학회지
2015 .01
-
Prevalence of Human Papillomavirus Infection and Genotype Distribution Determined via Real-Time PCR in a Korean Medical Check-up Population
한국미생물·생명공학회지
2018 .01
-
Production of Recombinant Human Papillomavirus Type 52 L1 Protein in Hansenula polymorpha Formed Virus-Like Particles
Journal of Microbiology and Biotechnology
2015 .01
-
부산지역 여성의 고위험군 인유두종 바이러스 유병률과 유전자형 분석
생명과학회지
2019 .11
-
Pine Needle Extract Applicable to Topical Treatment for the Prevention of Human Papillomavirus Infection
Journal of Microbiology and Biotechnology
2021 .01
-
세포학적 진단에 따른 인유두종 바이러스 유전자형의 분석
대한임상검사과학회지
2015 .01
-
High-Level Production of Human Papillomavirus (HPV) Type 16 L1 in Escherichia coli
Journal of Microbiology and Biotechnology
2016 .01
-
Investigation of Detected by Recent Various Human Papillomavirus from General Hospital in Seoul Area
대한임상검사과학회지
2016 .01
-
Development of a Novel Multiple Cross-Linking Spiral Amplification for Rapid and Sensitive Detection of HPV16 DNA
Journal of Microbiology and Biotechnology
2021 .01
-
Vaccine Development Program for Developing Countries, International Vaccine Institute
한국미생물학회 학술대회논문집
2016 .04
-
COVID-19 Vaccine Acceptance in the US and UK in the Early Phase of the Pandemic: AI-Generated Vaccines Hesitancy for Minors, and the Role of Governments
Journal of The Korean Data Analysis Society
2021 .01
-
A Study on the Evaluation of Test Vaccine against Commercial Vaccine Using Hepatitis A Vaccine Efficacy Evaluation Test
한국미생물학회 학술대회논문집
2022 .10
-
Molecular Analysis of the Interaction between Human PTPN21 and the Oncoprotein E7 from Human Papillomavirus Genotype 18
Molecules and Cells
2021 .01
이 논문의 저자 정보
이 논문과 함께 이용한 논문
최근 본 자료
댓글(0)
0
UCI(KEPA) : I410-ECN-0101-2023-594-000426718